Boost: Glaxo chief exec Emma Walmsley (pictured)GlaxoSmithKline posted rising sales yesterday – but shares slid because of fears over its vaccines division. In a boost for the pharma giant’s chief executive Emma Walmsley, turnover increased 8 per cent to £15.25billion, helped by cancer and HIV treatments, while profits climbed 18 Per cent to £2.5billion. That sparked an upgrade to its earnings outlook – although it lowered sales guidance for its vaccines arm. ‘The strong performance was broad-based, although the shingles vaccine Shingrix saw sales drop by 4 per cent,’ said Hargreaves Lansdown analyst Derren Nathan. ‘Even though GSK’s results beat expectations and full year guidance was upgraded, the vaccines arm is flagging.’Russ Mould, from AJ Bell, said: ‘Its shingles treatment is the problem child with a poor showing in the US.’ Shares slipped 2 per cent, or 30.5p, to 1512p
